Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with peripheral arterial disease (PAD).

Cardiovascular Systems, Inc. today announced that it has received CE (Conformité Européenne) Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360 is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD).

Essential Medical, Inc., a privately held medical device company, announced today that it has received CE mark approval for X-Seal, a new vascular closure device with superior handling and closure features. 

Northside Hospital Healthcare System continues to lead the Southeast in state-of-the-art surgical services with the introduction of three advanced robotic surgery technologies: The Magellan Robotic System, the da Vinci Xi Surgical System and the MAKOplasty surgical arm.

The Centers for Medicare & Medicaid Services (CMS) has determined that clinical sites that wish to participate in the newly announced CREST-2 carotid artery stenting (CAS) registry must receive accreditation. Accreditation for Cardiovascular Excellence (ACE) is a designated organization to provide these reviews. The objective of the CREST-2 Registry is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial. Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with CAS performed by experienced and skilled interventionists.

InspireMD, Inc., a leader in embolic protection systems (“EPS”), today announced positive results from the CARENET (CARotid Embolic protection study using microNET) Trial for its CGuardTM EPS. This trial demonstrates that the MicroNetTM covered CGuardmay offer important clinical benefits for patients undergoing carotid artery stenting (CAS).

Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic, Inc. augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for peripheral artery disease (PAD) in leg arteries above the knee.

The Spectranetics Corporation today announced that Eric Dippel, MD, at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, presented findings from the EXCITE ISR clinical trial proving Spectranetics' laser atherectomy devices, used with PTA (also known as balloon angioplasty), are clinically superior to PTA alone in both safety and efficacy, triggering a new standard in cardiovascular care.